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Abstract
Introduction: Arthralgia and MRI-detected subclinical inflammation can precede the development of clinically
evident rheumatoid arthritis (RA). However, part of the patients presenting with clinically suspect arthralgia (CSA) do
not progress to RA. In these ‘non-progressors’, we aimed to study the frequencies of spontaneous improvement of
arthralgia and its relation with the course of subclinical inflammation.
Methods: Between April 2012 and April 2015, 241 patients were considered at risk for RA based on the clinical
presentation and included in the CSA cohort. One hundred fifty-two patients with complete data on clinical follow-
up did not develop clinical arthritis, of which 98 underwent serial 1.5T MRI scans (wrist, MCP2–5, and MTP1–5 joints)
at baseline and after 2 years. MRI scans were scored for synovitis, tenosynovitis, and bone marrow oedema
(summed: MRI inflammation score). MRI scores were compared to scores of symptom-free persons.
Results: After a 2-year follow-up, 33% of the ‘non-progressors’ had complete resolution of symptoms; 67% had no
symptom resolution and were diagnosed as persistent CSA (44%), osteoarthritis (10%), and tendinomuscular
complaints (13%). With symptom-free controls as a reference, patients without resolution did not have increased
MRI scores at any time point. However, patients achieving resolution of symptoms had increased MRI inflammation
scores at baseline (4.0 vs. 2.6, p = 0.037), but not after 2 years (3.0 vs. 2.6; p = 0.57), and during follow-up, their MRI
inflammation score decreased significantly (p = 0.036).
Conclusions: A subgroup of CSA patients that did not progress to RA had spontaneous improvement of symptoms
and resolution of subclinical joint inflammation. This time relationship suggests that symptoms and inflammation
were causally related in these patients. Further research is needed to identify the mechanisms underlying the
resolution of inflammation.
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Introduction
Rheumatoid arthritis (RA) can be preceded by a phase of a
preclinical disease with signs and symptoms, in which joint
swelling cannot yet be identified through physical examin-
ation [1]. More than 90% of patients that develop RA had
MRI-detected subclinical inflammation in small joints in
the symptomatic phase of clinically suspect arthralgia
(CSA). However, of all patients that are identified as having
CSA, a large part (up to 80%) do not progress to clinically
evident RA [1]. Thus far, most longitudinal studies per-
formed in patients considered at risk for RA focussed on
the progression from arthralgia to RA [1, 2], since (early)
identification of individuals that will develop RA is a key
point from a clinician’s perspective. However, there is also a
group of patients that were considered at risk for RA but
over time do not develop RA, meaning that in hindsight,
they possibly have not been truly ‘pre-RA’. This subgroup
of patients is unexplored, and the course and outcome of
joint symptoms and subclinical inflammation in these pa-
tients are yet unknown. From a clinical perspective, know-
ledge of the course of these symptoms could be useful.
Moreover, despite non-progression, subclinical joint inflam-
mation could be present in (part of) these patients at first
presentation and comprehension on the natural course and
severity of subclinical inflammation, and its relationship
with spontaneous disappearance of arthralgia increases our
understanding on spontaneous resolution occurring in pa-
tients at risk phases of RA.
Longitudinal studies performed in the disease phase of
early undifferentiated arthritis (UA) have shown that clinical
synovitis resolved spontaneously in 10–40%, without
intervention with disease-modifying antirheumatic drugs
(DMARDs) [3, 4]. Based on these data, it can be hypothe-
sized that a similar (or even larger) percentage of patients
with CSA will show spontaneous resolution of joint symp-
toms. In addition, as arthralgia is associated with the
presence of local subclinical inflammation [5], it could be
hypothesized that there is a causal relation and that reso-
lution of symptoms is connected to the improvement of sub-
clinical inflammation presuming. Furthermore, it could be
presumed that patients with persistent symptoms had more
severe subclinical inflammation at presentation and during
follow-up compared to patients with symptom resolution.
We aimed to increase understanding of the course of
symptoms in patients that presented with CSA but did
not progress to RA. Therefore, the percentage of pa-
tients with symptom resolution and with persistent
symptoms during a 2-year follow-up was determined.
The scores of MRI-detected inflammation, and the time
relationship with the evanescence of symptoms, were
studied. Finally, MRI data were compared to MRI data
obtained from age-matched symptom-free persons from
the general population to estimate if MRI-detected joint
inflammation returned to normal values.
Methods
Patients
Between April 2012 and April 2015, 241 patients were in-
cluded in the CSA cohort: CSA patients had no clinically
evident arthritis, but recent-onset (< 1 year) arthralgia of
small joints, that was clinically considered at risk for RA by
the rheumatologist at first presentation at the outpatient
clinic. The cohort has been described before in [6]. Routine
follow-up visits were performed at 4, 12, and 24months. If
necessary (for instance, when the patient experienced more
symptoms or noticed a swollen joint), patients were seen in
between scheduled visits by their rheumatologist. Hence,
logistics were arranged such that patients in this cohort had
very easy access to rheumatologic care; should a patient de-
velop clinically evident IA, this was identified at the first op-
portunity. None of the patients was treated with DMARDs
(including corticosteroids) during the course of the study.
At the baseline visit, IgG ACPA (EliA CCP (anti-CCP2),
Phadia, Nieuwegein, the Netherlands) and IgM RF (as de-
scribed previously, in-house ELISA [7]) were determined.
The cut-off for ACPA positivity was > 7U/mL, and for RF
positivity, it was > 3.5 IU/mL.
A flowchart of inclusion is provided in Fig. 1. As this
study focused on patients that did not convert to RA over
time, 45 patients that were diagnosed with RA during
follow-up (clinical synovitis identified at the physical
examination by experienced rheumatologists, 19% out the
total n = 241) were excluded. From the subsequent total of
196 eligible patients, 44 patients were excluded because of
inappropriate inclusion (n = 5) or were lost to follow-up
during the 2-year course of the study (n = 39). This re-
sulted in complete clinical and follow-up data in 152 pa-
tients. Of these, 98 patients also had complete serial
imaging data at a 2-year follow-up. Reasons for incom-
plete serial imaging were contra-indications for contrast-
enhanced MR imaging and not willing to undergo (re-
peated) MR imaging. Indications of potential selection bias
at the different stages of the flowchart (n = 241: all patients
presenting with CSA, vs. n = 196: eligible non-converting
patients, vs. n = 152: non-converting patients with
complete follow-up data, vs. n = 98: non-converting pa-
tients with complete follow-up data and serial imaging)
were evaluated by comparing the baseline characteristics
between different patient groups.
All patients provided written informed consent. Ethics
approval was provided by the local medical ethical
committee.
Assessment of symptom resolution
The main outcome was patient-reported resolution of
symptoms. This was assessed at the routine follow-up
visits by asking patients to answer a written question if
they considered their symptoms completely resolved or
not (by literally inquiring ‘are your symptoms still
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present’, yes or no). Patients in whom initial presenting
features were resolved, but with new joint symptoms,
were classified in the non-resolution group. Resolution
of any related symptom (as judged by patients them-
selves) at the 24-month visit was used as a definition for
symptom resolution.
In addition to this main outcome, pain scores on a vis-
ual analogue scale (VAS; scale 0–10) were collected to
evaluate the robustness of the main outcome; the course
in VAS pain was also studied. Furthermore, 68 tender
joint counts (68-TJC) were studied. After 2 years with-
out conversion to clinical arthritis, patients were mostly
referred back to their GP with a clinical conclusion,
unless rheumatologist and/or patients felt that longer
follow-up at the rheumatology outpatient clinic was re-
quired. The clinical diagnosis after 2 years was also
studied.
Symptom-free persons
To make inferences on the presence and severity of
MRI-detected subclinical inflammation as compared to
the general population, MRI data from the 98 CSA
patients were matched to the data of MRI-detected
subclinical inflammation from symptom-free persons
[8]. Matching was based on age in a 1:1 ratio, since age
was previously proven to influence the severity of MRI-
detected subclinical inflammation [9]. Since sex was
previously demonstrated to have no effect on MRI-
detected inflammation [8, 10], matching was not per-
formed on sex. The 98 symptom-free persons had no
history of inflammatory rheumatic diseases, no joint
symptoms during the last month, and no evidence of
synovitis at physical examination. The symptom-free
persons were recruited from the general population, as
described in [8].
MRI
Unilateral MRIs of the wrist, MCP2–5, and MTP1–5
were performed at presentation with CSA (most painful
or in case of equally severe symptoms the dominant
side) and at 2-year follow-up (when follow-up ended) of
that same side. An ONI MSK Extreme 1.5T MRI scan-
ner (GE Healthcare, WI, USA) was used, as described
previously [1] and in Additional file 1: Patients were
Fig. 1 Flowchart of the different patient populations. FU, follow-up
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instructed not to use NSAIDs 24 h prior to MRI, with 22
patients reporting daily use of NSAIDs at baseline. MRIs
were evaluated for bone marrow oedema (BME; range
0–72), synovitis (range 0–33) [11], and tenosynovitis
(range 0–54) [12]. These 3 features were summed in the
total MRI inflammation score. Each MRI was scored by
2 readers, who belonged to a pool of 4 experienced
readers (all had interclass correlations ≥ 0.90, see Add-
itional file 1: Table S1). The mean scores of the 2 readers
were studied. All readers were blinded to the clinical
data and the order in time. MRI data were never
reported to the clinicians in any phase of the study. Add-
itional information on the scoring method is provided in
Additional file 1:
Analyses
Unpaired t tests were used to compare patients with
symptom-free persons. For analyses over time, paired t
tests were used. To evaluate if MRI inflammation scores
changed over time, analyses using measures of MRI-
detected subclinical inflammation were confined to
patients with a baseline total MRI inflammation score of
> 0, as a baseline score of 0 would not be able to further
decrease. Eighty-two patients (84%) had a baseline MRI
with a total MRI inflammation score > 0 (Fig. 1).
For consistency, total MRI inflammation scores on
group level for the same 82 patients were compared to
scores of age-matched symptom-free persons. Further-
more, a sub-analysis within autoantibody-positive
(ACPA- and/or RF-positive; 19% of patients) CSA pa-
tients was applied. Finally, sensitivity analyses were per-
formed on the patients meeting the EULAR definition of
arthralgia suspicious for progression to RA with ≥ 3
points (n = 63) [13]. Statistical analyses were carried out
using the Statistical Package for the Social Sciences
(SPSS; version 23.0). p values < 0.05 were considered sig-
nificant. Total MRI inflammation scores are reported as
mean.
Results
Patient characteristics
The baseline characteristics of patients at the different
stages in the flowchart (Fig. 1) did not show relevant dif-
ferences, as shown in Table 1. Baseline characteristics of
the patients with complete clinical follow-up and MRI
data at baseline and at 2-year follow-up (n = 98) are
demonstrated in Table 2. Patients presenting with CSA
that did not progress to RA were female in 74%, had a
mean age of 47 years, and a median 68-TJC of 5 joints,
and 19% carried RA-related autoantibodies (RF and/or
ACPA). These characteristics are comparable with
previous reports on patients from the Leiden CSA co-
hort [1, 14], although the percentage of autoantibody-
positive patients was lower in this study in non-
progressors, since the presence of autoantibodies is a risk
factor for progression to RA [1, 14] and autoantibodies
were thus less often observed in the non-converting pa-
tients. MRI-detected inflammation was not associated
with increased C-reactive protein levels (p = 0.38).
Resolution of symptoms over time
In the total group of 152 non-converting patients, 38%
(57 patients) indicated to have a resolution of symptoms
after 2 years of follow-up and 63% (95 patients) had no
symptom resolution. Similarly, in the group of 98
patients with serial imaging, 33% of patients (n = 32) re-
ported resolution of symptoms whereas 67% (n = 66 pa-
tients) did not. In addition, in the 54 patients without
serial MRIs, 25 experienced symptom resolution (46%)
whereas 29 patients did not experience resolution of
Table 1 Comparison of baseline patient characteristics between different stages of the flowchart as presented in Fig. 1
Patient characteristics N = 241 N = 196 N = 152 N = 98
Age in years, mean (SD) 44 (13) 44 (13) 45 (13) 47 (13)
Female sex, N (%) 187 (78) 152 (77) 118 (78) 73 (74)
Family history of RA, N (%) 71 (30) 52 (27) 43 (28) 28 (29)
Symptom duration in weeks, median (IQR) 18 (10–48) 17 (9–30) 17 (9–33) 17 (9–43)
Presence of morning stiffness ≥ 60 min, N (%) 80 (33) 61 (35) 49 (32) 29 (30)
68-TJC, median (IQR) 6 (3–10) 6 (2–11) 6 (2–10) 5 (2–10)
VAS pain score, median (IQR) 5 (3–7) 5 (3–7) 5 (3–7) 5 (3–6)
≥ 3 items on EULAR definition of arthralgia suspicious for progression to RA [13], N (%) 178 (74) 141 (72) 100 (66) 63 (64)
Increased CRP (≥ 5 mg/L), N (%) 53 (22) 39 (20) 29 (19) 19 (19)
Autoantibody status
Negative for IgM-RF and ACPA, N (%) 184 (76) 166 (84) 125 (82) 79 (81)
ACPA- or RF-positive, N (%) 57 (24) 31 (16) 27 (18) 19 (19)
ACPA anti-citrullinated peptide antibody (positive if ≥ 7 U/mL), CRP C-reactive protein, IgM-RF immunoglobulin M rheumatoid factor (positive if ≥ 3.5 IU/mL), IQR
interquartile range, RA rheumatoid arthritis, SD standard deviation, TJC tender joint count
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symptoms (54%). A chi-squared test comparing the
number of patients experiencing symptom resolution in
the groups of patients with and without serial MRI
showed no significant difference (p = 0.09). The percent-
ages of patients with complete clinical and imaging data
indicating to experience resolution of symptoms (n = 32)
at the follow-up visits at 4, 12, and 24months are indi-
cated in Fig. 2.
Within the patients that had complete clinical and
MRI data, the patients that indicated to have a reso-
lution of symptoms had a larger decrease in VAS pain
scores over time than patients without a resolution of
symptoms (decrease in VAS pain of 2.9 vs. 0.77; p <
0.001; Fig. 3). At baseline, the median 68-TJC was 4 in
patients with a resolution and 6 in patients without reso-
lution. After 2 years, the median TJC was 0 in patients
with symptom resolution, whilst this was significantly
higher in patients without symptom resolution (Mann-
Whitney U test: p = 0.02). Several other characteristics of
both groups evaluated at the 2-year follow-up are pre-
sented in Table 3. Although the resolution of symptoms
was initially assessed with one question, these results
show that patients that reported to have a symptom
resolution improved in other measures for pain.
Patients with remaining symptoms were diagnosed as
persistent CSA because of persistent inflammatory type
of arthralgia according to the rheumatologists (n = 43;
44% of all non-converters), osteoarthritis (n = 10; 10% of
all non-converters), and tendinomuscular complaints
(n = 13; 13% of all non-converters).
At disease presentation, the proportion of patients that
used NSAIDs on a daily basis was equally distributed be-
tween patients with or without resolution of symptoms
(22% vs. 23%; p = 0.89). After the 2-year follow-up, 9% of
the patients with persistent symptoms used NSAIDs on
a daily basis, whilst NSAIDs were not used in the group
Table 2 Baseline patient characteristics of the clinically suspect arthralgia patients with complete clinical follow-up (N = 152) and
complete clinical follow-up as well as MRI data at baseline at 2-year follow-up (N = 98)
Patient characteristics Complete clinical follow-up (N = 152) Complete clinical follow-up and MRI data (N = 98)
Symptom resolution
(n = 57)
No symptom resolution
(n = 95)
Symptom resolution
(n = 32)
No symptom resolution
(n = 66)
Age in years, mean (SD) 44 (13) 46 (13) 46 (14) 47 (13)
Female sex, N (%) 40 (70) 79 (82) 20 (63) 53 (80)
Family history of RA, N (%) 17 (30) 26 (27) 10 (31) 18 (27)
Symptom duration in weeks*,
median (IQR)
17 (9–30) 17 (9–41) 18 (15–32) 17 (9–50)
Morning stiffness ≥ 60 min, N (%) 22 (39) 27 (28) 10 (31) 19 (29)
68-TJC*, median (IQR) 5 (2–8) 6 (2–12) 4 (2–7) 6 (2–13)
≥ 4 tender joints, N (%) 33 (58) 61 (64) 18 (56) 43 (65)
Increased CRP (≥ 5 mg/L), N (%) 12 (21) 17 (18) 9 (28) 10 (15)
Autoantibody status
Negative for IgM-RF and ACPA, N
(%)
43 (75) 71 (75) 25 (78) 54 (82)
ACPA- or RF-positive, N (%) 9 (16) 18 (19) 7 (22) 12 (18)
ACPA-positive, N (%) 5 (9) 6 (6) 3 (9) 4 (6)
ACPA anti-citrullinated peptide antibody (positive if ≥ 7 U/mL), CRP C-reactive protein, IgM-RF immunoglobulin M rheumatoid factor (positive if ≥ 3.5 IU/mL), IQR
interquartile range, RA rheumatoid arthritis, SD standard deviation, TJC tender joint count, VAS visual analogue scale
*Missing data were as follows: symptom duration in weeks (n = 4) and 68-TJC (n = 1)
Fig. 2 Percentage of patients reporting resolution of symptoms per
follow-up visit presented for all patients (N = 32) that had a
resolution of symptoms. Percentage of patients reporting resolution
of symptoms per regular follow-up visit at 4, 12, and 24months
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with symptom resolution, which is in line with the ab-
sence of symptoms.
Clinical characteristics of patients with and without
symptom resolution
Patients that later on achieved symptom resolution had
no differences in baseline characteristics at baseline;
Table 2 displays the patient characteristics for the 152
non-converting patients with complete clinical follow-up
data, as well as the 98 non-converting patients with ser-
ial MRIs. The mean baseline total MRI inflammation
score was slightly higher in patients that would eventu-
ally achieve symptom resolution (3.5) as compared to
patients with persistent symptoms (2.7), but this was not
statistically significant (p = 0.33).
Association between symptom resolution and
improvement of MRI inflammation
The mean total MRI inflammation scores of the 82 pa-
tients with a baseline total MRI inflammation score > 0
were compared to the MRI scores of similar age-matched
symptom-free persons to infer if the MRI inflammation
scores at the different time points exceeded the level of
MRI-detected inflammation prevalent in the general
population. Other characteristics of the symptom-free per-
sons are provided in Additional file 1: Table S2.
In the group of CSA patients that achieved resolution
of symptoms over time, the mean MRI inflammation
score was higher than that of symptom-free persons at
baseline (4.0 vs. 2.6; p = 0.04; Fig. 4). In contrast, the pa-
tients that did not report a resolution of symptoms did
not have higher MRI inflammation scores at baseline
(mean 3.3 and 2.9; p = 0.26; Fig. 4).
After the 2-year follow-up, the mean total MRI in-
flammation score in patients with resolution of symp-
toms decreased to a level similar to that of symptom-
free persons (3.0 vs. 2.6; p = 0.57; Fig. 4), whereas the
patients without a resolution of symptoms still had
no differences in their total MRI inflammation scores
(mean 2.7 vs. 2.9; p = 0.68; Fig. 4). Comparison of the
individual inflammatory features as detected by MRI
are provided in Additional file 1: Figure S1; the
decrease in the total MRI inflammation score was
mostly due to a decrease in tenosynovitis and
synovitis.
Finally, the difference of the total MRI inflammation
scores over time was evaluated between baseline and 2-
year follow-up (Fig. 4). The CSA patients with a reso-
lution of symptoms had a statistically significant
decrease in MRI inflammation score (difference 0.98;
paired t test: p = 0.036). In the CSA patients that did not
convert to RA and had no resolution of symptoms, the
Fig. 3 VAS pain scores over time for patients with and without resolution of symptoms (N = 98). *Significance at the p < 0.05 level, **significance
at the p < 0.01 level
Table 3 Characteristics of the 98 patients with and without a resolution of symptoms at the 2-year follow-up
Patient characteristics Symptom resolution (n = 32) No symptom resolution (n = 66) p value
68-TJC, median (IQR) 0 (0–0) 1 (0–4) 0.02
Presence of morning stiffness ≥ 60 min, N (%) 5 (16) 14 (21) 0.56
HAQ score, mean (SD) 0.18 (0.40) 0.60 (0.50) 0.09
VAS pain score, mean (SD) 0.87 (1.5) 4.2 (2.4) < 0.001
VAS fatigue score, mean (SD) 3.7 (3.3) 5.6 (2.6) 0.003
IQR interquartile range, SD standard deviation, TJC tender joint count, VAS visual analogue scale (range 0–10)
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decrease was smaller (difference 0.44) and did not reach
statistical significance (paired t test: p = 0.09).
Together, in patients with a resolution of symptoms,
MRI inflammation scores were increased at the first
presentation and normalized after symptom resolution,
whereas patients that remained having symptoms (but
did not progress to RA) did not have increased inflam-
mation scores at any time point, with age-matched con-
trols as a reference.
Although the group of patients without a resolution of
symptoms was a heterogenous group in terms of final
diagnosis, none of the separate diagnoses had a significant
difference in MRI inflammation score over time: persistent
CSA (p = 0.37), osteoarthritis (p = 0.60), and tendinomus-
cular complaints (p = 0.79). Separate matching of the pa-
tients with persistent CSA compared to symptom-free
persons revealed no differences in the total MRI inflam-
mation score at baseline (3.4 vs. 2.8; p = 0.25), or at the 2-
year follow-up (2.6 vs. 2.8; p = 0.83). Matching of patients
finally diagnosed with osteoarthritis and tendinomuscular
complaints with symptom-free persons was not performed
due to small patient numbers.
Sub-analyses: autoantibody-positive patients
Although the presence of autoantibodies in CSA is asso-
ciated with an increased risk of RA development, part of
the patients with autoantibodies did not progress. In line
with previous studies that reported a PPV of > 60% for
ACPA-positive patients [1, 14] part of the autoantibody-
positive patients did not progress to RA during the 2-
year follow-up. In our data, 19% of the non-converting
patients were either ACPA- or RF-positive. There was
no conversion in ACPA or RF status in any direction
over 2 years’ time.
Within the group of ACPA- or RF-positive non-
converting patients (n = 19), 7 patients (37%) had symp-
tom resolution over time and 12 patients (63%) had no
resolution of symptom. The total MRI inflammation
score decreased from 5.0 to 3.3 (difference 1.8; paired t
test: p = 0.21) in patients with a resolution of symptoms.
In patients without a resolution of complaints, the total
MRI inflammation score reduced from 2.4 to 1.9 (differ-
ence 0.55; paired t test: p = 0.19). Comparison of MRI
scores with symptom-free persons, as stratified by the
resolution of symptoms, was not performed due to in-
sufficient statistical power.
Sensitivity analysis: patients meeting the EULAR
definition
A sub-analysis was performed in patients that met the
EULAR definition of arthralgia suspicious for progres-
sion to RA [13]. Sixty-four percent of the CSA patients
that did not develop RA fulfilled the EULAR definition
of arthralgia suspicious for progression to rheumatoid
arthritis with ≥ 3 items present. Also in this subgroup,
37% of the patients achieved spontaneous resolution of
symptoms.
Similar findings were obtained when patients meeting
the EULAR definition and with a baseline total MRI in-
flammation score > 0 were compared to MRI scores of
similar age-matched symptom-free persons. The patients
experiencing resolution had higher MRI inflammation
scores at disease presentation than symptom-free con-
trols (p = 0.04), whilst the scores were no longer in-
creased at the time of symptom resolution (p = 0.53).
Patients without a resolution of symptoms (that did not
progress to RA) did not have significantly increased MRI
inflammation scores at any time point (Additional file 1:
Fig. 4 Mean total MRI inflammation scores over time for patients with and without resolution of symptoms (N = 82). The grey area indicates the
mean and 95% confidence interval (dashed lines specify the upper and lower limit of the interval) of the total MRI inflammation score in age-
matched symptom-free persons. Considered in this figure are patients with a baseline total MRI inflammation score > 0. At baseline, in the group
without resolution of complaints, the mean total MRI inflammation score was not different as compared to symptoms-free persons (p = 0.26).
Patients with resolution did have higher scores than symptoms-free persons (p = 0.04). After the 2-year follow-up, patients without and with a
resolution of symptoms both did not have higher scores (p = 0.68 and p = 0.57, respectively). *Significance at the p < 0.01 level;
N.S., non-significance
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Table S3). Over time, MRI inflammation scores de-
creased in patients with symptom resolution (4.6 to 3.1;
p = 0.02). In patients without a symptom resolution,
scores did not decrease: 3.3 to 3.2; p = 0.67.
Discussion
Patients with clinically suspect arthralgia are considered
to be at risk for RA development by their rheumatolo-
gists. Most research done in the field of ‘RA risk’ is fo-
cussed on the subgroup of patients that indeed progress
to RA. However, a large proportion of the patients that
are considered to have an increased risk do not actually
develop IA and RA. Here, we studied the group of non-
converting patients and observed various outcomes. A
considerable part of the patients that initially had pre-
sented with CSA continued to be characterized as CSA
after a 2-year follow-up. A smaller part of the patients
developed other explanations for their complaints. Inter-
estingly, both latter groups of patients did not have in-
creased MRI inflammation scores of small joints as
compared to age-matched symptom-free persons. Fur-
thermore, approximately one third of the non-
converting patients had a resolution of symptoms over
time. These patients had increased MRI-detected sub-
clinical inflammation at baseline, which also resolved
over time. This time relationship suggests that the sub-
clinical inflammation was related to the presence of
symptoms and the phenotype of CSA. In our view, this
is the most interesting group of patients: these patients
may indeed have been pre-RA but one of several final
switches required for actual progression to RA were not
turned ‘on’ and the disease process resolved without
intervention.
Our study is the first to quantify the percentage of pa-
tients presenting with CSA that will have a resolution of
symptoms over time. It consists of one third of all non-
progressing patients and 27% of all patients that were
identified as having CSA by rheumatologists. Interest-
ingly, previous studies done in patients with UA showed
that clinical synovitis resolved in 10–40% [3, 4], which is
a similar range of spontaneous dissolvement. Similar as
seen here, patients with spontaneous resolution were
more often autoantibody-negative than patients with
progression to arthritis. Despite the association with the
absence of autoantibodies, the pathophysiologic mecha-
nisms mediating spontaneous resolution or absence of
progression are not elucidated yet. Our study served to
identify this group of patients. Future studies are re-
quired to increase our understanding of the biological
mechanisms involved.
This study had several limitations. First, patients were
analysed during the 2-year follow-up, and patients that
did not progress to RA could still develop IA after the
follow-up of the study ended. However, as the Leiden
University Medical Centre is the only referral centre in
the region, it is unlikely that patients will visit another
centre should symptoms reoccur. This allowed us to
study if patients had returned to our Rheumatology
Department after the formal final regular follow-up visit
at 2 years. After an average of 5 years after the baseline
visit, none of the patients had returned to be diagnosed
with RA, indicating that patients truly did not develop
RA. In addition, patients that had indicated that symp-
toms had disappeared after 2 years could theoretically
experience renewed symptoms later on in life. However,
this would not affect the current findings that resolution
of symptoms was paralleled by resolution of subclinical
inflammation.
A further limitation of our study is the small number
of patients included. Especially the number of patients
that were ACPA-positive and not progressed to RA is
small, which warrants future studies with larger numbers
of included patients to allow statistically more powerful
analyses than our current, mostly exploratory, analyses.
Another limitation is that part of the patients did not
complete the follow-up or did not consent to undergo
another MRI. Although missing data was presumably
not at random as patients with less severe symptoms are
more likely to retract from the follow-up, the patient
characteristics of the different groups were quite similar
(Table 1), arguing against a major bias. However, the
percentage of patients experiencing symptom resolution
in the group that did not have complete imaging data
over 2 years was slightly larger (46%) than the percent-
age of patients with complete imaging data (33%) which
could be a potential source of bias, although the differ-
ence was not significantly different. Possibly, patients
who experienced symptom resolution slightly less often
felt the need to undergo imaging studies after 2 years.
Finally, since patients with baseline MRI scores of > 0
were studied, regression to the mean could have oc-
curred. Furthermore, scores of MRI-detected inflamma-
tion were studied on a group level rather than joint level
to decrease the possibility of type 1 error due to multiple
testing. Nevertheless, we demonstrated that baseline
scores in the patients with resolution significantly
exceeded the level of MRI-detected subclinical inflam-
mation of symptom-free persons, but not in the patients
without resolution of symptoms.
The main outcome was a patient-reported resolution
of symptoms. No validated questionnaire exists of
patients with arthralgia at risk for RA, and we assessed
this outcome using a single written question. The
robustness of this outcome was illustrated by decreasing
VAS pain scores and diminishing tender joint counts in
the patients with a resolution, and therefore, we consid-
ered this to be a valid question that was interpreted well
and uniformly by patients themselves.
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Finally, DMARD therapy (including steroids) was not
allowed and not prescribed during the course of the
CSA study, but NSAIDs were allowed. NSAIDs were
stopped before MR imaging. It could be questioned if
NSAIDs played a role in disease resolution. However,
NSAIDs are generally not considered as disease-
modifying therapy, and the frequency of NSAIDs use at
baseline was similar in patients with and without a
symptom resolution.
In conclusion, one third of all patients with CSA that
did not convert to IA or RA during the 2-year follow-up
had resolution of symptoms and improvement of subclin-
ical joint inflammation. This time relationship is suggest-
ive for a causal relation of the subclinical inflammation
and the phenotypic presentation of CSA. Further research
is needed to identify the mechanisms that are involved in
the resolution of disease processes.
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